Global Hepatic Encephalopathy Treatment Market Projected to Reach USD 2971.51 Million by 2033, Growing at a CAGR of 6.5%

The global hepatic encephalopathy treatment market achieved a market value of USD 1,486.39 million in 2022 and is poised for significant growth, expected to accumulate USD 2,971.51 million by 2033. This expansion represents a robust Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period from 2023 to 2033.

Key factors driving this growth include:

1. Rising Prevalence of Liver Diseases: The increasing incidence of liver conditions such as cirrhosis and non-alcoholic fatty liver disease (NAFLD) is significantly contributing to the demand for effective hepatic encephalopathy treatments.
2. Growing Awareness and Diagnosis: Enhanced awareness of hepatic encephalopathy and improvements in diagnostic capabilities are leading to earlier detection and treatment, fostering market expansion.
3. Advancements in Treatment Options: Ongoing research and development efforts are yielding new therapies and improved treatment protocols that are addressing the needs of patients suffering from hepatic encephalopathy.
4. Aging Population: As the global population ages, the prevalence of liver-related disorders is expected to rise, further driving the demand for hepatic encephalopathy treatments.

Historically, the market registered a CAGR of 3.9% from 2018 to 2022, reflecting a steady upward trend. As the hepatic encephalopathy treatment market continues to evolve, stakeholders are encouraged to explore emerging opportunities to meet the growing needs of patients.

Hepatic encephalopathy (HE) treatment aims to manage the symptoms and underlying causes of the condition. HE is a condition where the liver is unable to remove toxins from the bloodstream effectively, leading to a buildup of toxins in the brain. The condition can range from mild to severe, with symptoms such as confusion, personality changes, tremors, and even coma.

The treatment of HE typically involves managing the underlying cause of the condition, such as liver disease or cirrhosis. This may involve treating the underlying liver disease or cirrhosis, such as through medication, diet, or lifestyle changes.

Which are Some Prominent Drivers of Hepatic Encephalopathy Treatment Market?

Prevalence of liver diseases driving market growth for hepatic encephalopathy treatment market

The rising incidence of liver diseases such as cirrhosis, hepatitis, and fatty liver disease is a significant driver of the HE treatment market. These conditions are major risk factors for the development of HE, and the increasing prevalence of liver diseases is expected to drive the demand for HE treatment.

As awareness of HE increases among patients and healthcare professionals, there is a growing emphasis on early diagnosis and treatment. This is expected to drive the demand for HE treatment. There have been several technological advancements in HE treatment, such as the development of new medications and therapies. For example, the use of lactulose and rifaximin has become the standard of care in the treatment of HE, and there is ongoing research into new medications and therapies.

As healthcare spending increases globally, there is a growing demand for effective and innovative treatments for liver diseases and HE. The elderly population is at an increased risk of developing liver diseases and HE, and the growing geriatric population is expected to drive the demand for HE treatment.

Market Competition

Key players in the hepatic encephalopathy treatment market are Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.

• Mallinckrodt Pharmaceuticals has developed Vecamyl (mecamylamine hydrochloride) tablets. Vecamyl is an oral medication used to reduce the symptoms of HE, including confusion, irritability, and restlessness. It works by blocking the action of acetylcholine, a neurotransmitter that is involved in the development of HE.
• GSK has developed lactulose, a synthetic sugar that is commonly used in the treatment of HE. Lactulose works by decreasing the amount of ammonia in the gut, which can help prevent the development of HE and alleviate its symptoms.

Key Companies Profiled

• Mallinckrodt Pharmaceuticals
• Salix Pharmaceuticals
• GlaxoSmithKline plc.
• Pfizer Inc.
• ASKA Pharmaceutical Co., Ltd.
• Bausch Health
• Johnson & Johnson Services, Inc.
• Janssen Global Services
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.

A Full Report Overview

Key Segments Profiled in the Hepatic Encephalopathy Treatment Industry Survey

Drug Class:

• Antibiotics
• Laxatives
• L-ornithine
• L-aspartate

Diagnosis:

• Blood Tests
• CT Scan
• Liver Functioning Tests

Route of Administration:

• Oral
• Injectable
• Intravenous
• Others

Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube